Evaluating liquid biopsy for cancer diagnosis
Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
This study tests if a blood test that looks for cancer DNA can help doctors find problems in patients with advanced cancer, comparing it to the usual tissue tests.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 238 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Antoine Lacassagne Academic / other |
| Locations | 1 site (Nice) |
| Trial ID | NCT06606366 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of liquid biopsy, specifically through circulating tumor DNA analysis, in identifying molecular abnormalities in patients with advanced-stage malignant solid tumors. The study compares the results of liquid biopsies to traditional solid biopsies, which are considered the gold standard. Participants will provide blood samples for analysis, and the findings will be discussed in a multidisciplinary molecular biology meeting to guide patient management.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with advanced-stage malignant solid tumors who are eligible for a multidisciplinary molecular biology meeting.
Not a fit: Patients with previous or concurrent cancers diagnosed or treated within the last 5 years may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive method for diagnosing cancer and identifying treatment options.
How similar studies have performed: Other studies have shown promising results with liquid biopsy approaches, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Over 18 years old. * Advanced-stage malignant solid tumor managed in a non-curative context. * Patient eligible for Multidisciplinary molecular biology meeting with available archived tumor material (frozen or FFPE block, less than 5 years old) or a biopsiable tumor lesion. * Performance status of 0 or 1. * Patient able to read, write, and understand the French language. * Patient has read the information sheet and signed the informed consent. * Patient has social security coverage. Exclusion Criteria: * Previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder. * Severe or uncontrolled systemic disease. * Any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures. * Patient considered a vulnerable person; vulnerable persons are defined in Articles L1121-5 to L1121-8: * Pregnant women, women in labor, and breastfeeding mothers, * Persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8, * Persons admitted to a healthcare or social institution for reasons other than research, * Adults unable to give their consent.
Where this trial is running
Nice
- Centre Antoine Lacassagne — Nice, France (Recruiting)
Study contacts
- Study coordinator: Study coordinator
- Email: DRCI-Promotion@nice.unicancer.fr
- Phone: +33 04 92 03 14 76
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.